Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eddy Pasquier

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Acta Paediatrica (Oslo, Norway : 1992)|July 8, 2016
Metronomics during palliative care in paediatric oncology? For sure! But handle me with careNicolas Andre, Eddy Pasquier
Current Cancer Drug Targets|August 20, 2010
Endothelial progenitor cells: hope beyond controversyEddy Pasquier, Sergio Dias
Nature Clinical Practice. Oncology|January 31, 2009
Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'Nicolas André, Eddy Pasquier
Nature|July 17, 2009
For cancer, seek and destroy or live and let live?Nicolas André, Eddy Pasquier
IUBMB Life|April 2, 2008
Microtubules: a dynamic target in cancer therapyEddy Pasquier, Maria Kavallaris
Current Cancer Drug Targets|February 4, 2011
New therapeutic advances and perspectives in tumour angiogenesisEddy Pasquier, Nicolas André
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 8, 2010
Can the drug-driven dependency and deprivation effect be used as a therapeutic tool in tuberculous patients?Nicolas André, Eddy Pasquier
Nature Reviews. Clinical Oncology|June 29, 2016
Paediatrics: Metronomics - fulfilling unmet needs beyond level A evidenceNicolas André, Shripad Banavali, Eddy Pasquier
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 23, 2006
Microtubule-targeting agents in angiogenesis: where do we stand?Eddy Pasquier, Stéphane Honoré, Diane Braguer
Lancet (London, England)|August 27, 2013
Investment in cancer studies in countries of low and middle incomeNicolas Andre, Brendon Guercio, Eddy Pasquier
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Acta Paediatrica (Oslo, Norway : 1992)|July 8, 2016
Metronomics during palliative care in paediatric oncology? For sure! But handle me with careNicolas Andre, Eddy Pasquier
Current Cancer Drug Targets|August 20, 2010
Endothelial progenitor cells: hope beyond controversyEddy Pasquier, Sergio Dias
Nature Clinical Practice. Oncology|January 31, 2009
Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'Nicolas André, Eddy Pasquier
Nature|July 17, 2009
For cancer, seek and destroy or live and let live?Nicolas André, Eddy Pasquier
IUBMB Life|April 2, 2008
Microtubules: a dynamic target in cancer therapyEddy Pasquier, Maria Kavallaris
Current Cancer Drug Targets|February 4, 2011
New therapeutic advances and perspectives in tumour angiogenesisEddy Pasquier, Nicolas André
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 8, 2010
Can the drug-driven dependency and deprivation effect be used as a therapeutic tool in tuberculous patients?Nicolas André, Eddy Pasquier
Nature Reviews. Clinical Oncology|June 29, 2016
Paediatrics: Metronomics - fulfilling unmet needs beyond level A evidenceNicolas André, Shripad Banavali, Eddy Pasquier
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 23, 2006
Microtubule-targeting agents in angiogenesis: where do we stand?Eddy Pasquier, Stéphane Honoré, Diane Braguer
Lancet (London, England)|August 27, 2013
Investment in cancer studies in countries of low and middle incomeNicolas Andre, Brendon Guercio, Eddy Pasquier
Pageof 9